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In the context of modern cancer chemotherapeutics, cancer survivors are living longer and
being exposed to potential comorbidities related to non-cancer side effects of such treat-
ments. With close monitoring of cancer patients receiving potentially cardiotoxic medical
therapies, oncologists, and cardiologists alike are identifying patients in both clinical and
subclinical phases of cardiovascular disease related to such chemotherapies. Specifically,
cardiotoxicity at the level of the myocardium and potential for the development of heart fail-
ure are becoming a growing concern with increasing survival of cancer patients.Traditional
chemotherapeutic agents used commonly in the treatment of breast cancer and hemato-
logic malignancies, such as anthracyclines and HER-2 antagonists, are well known to be
associated with cardiovascular sequelae. Patients often present without symptoms and an
abnormal cardiac imaging study performed as part of routine evaluation of patients receiv-
ing cardiotoxic therapies. Additionally, patients can present with signs and symptoms of
cardiovascular disease months to years after receiving the chemotherapies. As the under-
standing of the physiology underlying the various cancers has grown, therapies have been
developed that target specific molecules that represent key aspects of physiologic path-
ways responsible for cancer growth. Inhibition of these pathways, such as those involving
tyrosine kinases, has lead to the potential for cardiotoxicity as well. In view of the potential
cardiotoxicity of specific chemotherapies, there is a growing interest in identifying patients
who are at risk of cardiotoxicity prior to becoming symptomatic or developing cardiotoxicity
that may limit the use of potentially life-saving chemotherapy agents. Serological markers
and novel cardiac imaging techniques have become the source of many investigations with
the goal of screening patients for pre-clinical cardiotoxicity. Additionally, studies have been
performed.
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INTRODUCTION
Improving survival in patients with cancer is related to early
diagnosis and novel, increasingly effective therapies. This has
consequently exposed patients to increasingly more frequent car-
diovascular (CV) morbidities and mortalities related to estab-
lished risk factors. In addition, the chemotherapy (CT) itself
has become a “risk factor” for CV disease in patients with can-
cer. The CV side effects of these chemotherapeutic agents are
becoming increasingly apparent and prevalent based on close
clinical monitoring, the use of serological markers, such as tro-
ponins and BNP, and finally by using standard and novel imaging
techniques, which includes nuclear imaging, echocardiograms,
and MRI.
Cardiologists are taking on a more prominent role in the
care of patients with cardiotoxicity from agents used to treat
breast cancer as well as hematological and other malignancies.
Early identification of patients who are at risk for chemotherapy-
induced cardiotoxicity (CIC) should be a primary goal in the
development of individualized therapeutic strategies and inter-
ventions in cancer patients (Albini et al., 2010). The therapeutic
options have been studied in only a handful of trials, including the
traditional heart failure (HF) medications such ACE inhibitors,
angiotensin receptor antagonists (ARA), and beta blockers. Tra-
ditional chemotherapeutic agents, such as anthracyclines (AC)
have been known to cause CV sequelae for many years, however
now with the development of more targeted drugs such as mon-
oclonal antibodies and tyrosine kinase inhibitors (TKI), new CV
side effects are becoming more prevalent. The topics of CT and
cardiotoxicity, its therapies, prevention, and potential predictors
will be reviewed.
CHEMOTHERAPEUTIC AGENTS
There is an extensive list of chemotherapeutic agents that have
the potential to induce HF or predispose patients to cardiotox-
icity of the myocardium, including anthracycline agents, certain
hormonal therapies like Trastuzumab, TKI, 5 Fluorouracil and its
related compounds, and several others. The focus of this review is
on the therapies that have been recently evaluated in the context of
their impact on not only clinical HF presentation but on cardiac
biomarkers and imaging techniques.
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ANTHRACYCLINES
Anthracyclines are one of the most widespread chemotherapeutic
agents often used for the treatment of lymphomas, hematological
malignancies, breast carcinomas, and sarcomas. They are a class of
drugs derived from the Streptomyces bacterium and prevent DNA
transcription and replication and potentially generate free radicals
that can damage the DNA (Chaires, 1990).
The true incidence of chronic cardiotoxicity related to AC has
been difficult to determine accurately because the follow-up dura-
tion has been brief in most clinical trials. Moreover, studies have
variable definitions of cardiotoxicity and different methods used
for measurement of cardiac function (Barrett-Lee et al., 2009).
Initially, early studies demonstrated that the incidence of HF was
approximately 3.0% in patients receiving a cumulative dose of
doxorubicin of 400 mg/m2, 7.5% at 550 mg/m2, and 18.0% at
700 mg/m2 (Von Hoff et al., 1979). In a retrospective study done
years later, the incidence was found to be 5.0% at a cumulative dose
of 400 mg/m2, 26.0% at 550 mg/m2, and 48.0% at 700 mg/m2 and
it was hypothesized that AC-induced cardiotoxicity had been pre-
viously under estimated (Swain et al., 2003). More than one half
of all patients exposed to AC will present with some degree of car-
diac dysfunction 10–20 years after CT (Steinhertz et al., 1991) and
AC-induced cardiomyopathy has been associated with a 2-years
mortality rate up to 60% (Cardinale et al., 2010).
Anthracycline’s are associated with an irreversible form of
dilated cardiomyopathy and dose dependant cardiotoxicity (Yeh
et al., 2004). They have revolutionized the management of certain
malignancies, but there remains a clinically significant incidence
of cardiotoxicity associated with these drugs. AC-induced car-
diotoxicity may be acute, subacute, or chronic. Acute or subacute
cardiotoxicity is rare, usually independent of dose, and reversible.
It may present as asymptomatic electrocardiographic changes,
arrhythmias, heart block, or more rarely an acute myocardi-
tis. It can potentially resolve after discontinuation of the ther-
apy. Chronic or late-onset cardiotoxicity may present months
or years after infusion and tends to be an irreversible car-
diomyopathy (Barrett-Lee et al., 2009). The onset of AC-induced
cardiac dysfunction, even asymptomatic may negatively affects
cancer patient’s cardiac outcomes and limit their therapeutic
opportunities (Cardinale et al., 2006).
MONOCLONAL ANTIBODY
Trastuzumab (herceptin)
Trastuzumab is a humanized monoclonal antibody aimed at tar-
geting ERB2 (epidermal growth factor receptor 2) on the surface
of ERB2 overexpressing tumor cells. Trastuzumab is approved for
the treatment of ERB2 positive breast cancer in both the metasta-
tic and adjuvant settings (Carver, 2010). Trastuzumab associated
cardiac dysfunction was first identified in metastatic breast cancer
trials and second to AC, it is the most common chemotherapeutic
agent associated with left ventricular dysfunction (Witteles et al.,
2011).
Slamon et al. (2001) were amongst the first to iden-
tify trastuzumab-related cardiotoxicity. Women with progressive
metastatic breast cancer, with overexpression of HER-2, who had
not previously received CT for metastatic disease, were included
in this study. Patients were randomly assigned to receive standard
CT alone or CT plus trastuzumab. The most noted adverse event
was cardiac dysfunction, which occurred in 27% of those who
received AC, cyclophosphamide, and trastuzumab; 13% of those
given paclitaxel and trastuzumab and 1% of those given pacli-
taxel alone. The incidence of NYHA 3/4 or 4/4 HF was highest
among patients who had received an AC, cyclophosphamide, and
trastuzumab.
Unlike the cardiac dysfunction caused by AC, that associated
with trastuzumab is unrelated to dose and reversible in many
cases. Thirty eight patients with HER-2/neu-positive breast can-
cer were referred for suspected trastuzumab-related cardiotoxicity
and were studied over a 4-years period (Ewer et al., 2005). After
a median of 4.5 months of trastuzumab therapy, the mean LVEF
decreased below baseline. Once left ventricular dysfunction or HF
was identified, trastuzumab was discontinued. The patients were
either treated for cardiac dysfunction or observed. During a period
of approximately 1.5 months, the LVEF returned toward baseline
and at 1–3 months, improved in all of the patients except the
one patient who continued on trastuzumab for palliative reasons.
Nine patients underwent right ventricular endomyocardial biopsy,
which did not demonstrate any evidence of typical AC-related
changes. Further studies are warranted in order to investigate the
ideal timing between AC and trastuzumab therapy in order to
minimize cardiac damage.
Tyrosine kinase inhibitors
Tyrosine kinase inhibitor’s are molecules that were designed to
target TKs which are overexpressed in cancer cells. However, they
may also inhibit normal aspects of TK functions in non-cancerous
cells and may lead to undesirable side effects such as cardiotoxi-
city and left ventricular failure (Chu et al., 2007). They have led
to a tremendous advancement in the treatment of malignancies
such as breast cancer, renal cell carcinoma (RCC), lymphoma, and
gastrointestinal stromal tumors (GIST).
Imatinib (gleevec)
Imatinib is a TKI, of the ABL kinase, which has been approved
and effective for the treatment of malignancies such as chronic
myeloid leukemia (CML) and GIST (Garcia-Alvarez et al., 2010).
Cardiotoxicity associated with Imatinib has not been well estab-
lished. Early clinical trials investigating the utility of Imatinib in
GIST treatment had not consistently monitored cardiac function.
In the International randomized Study of Interferon versus
STI571 (IRIS) study there was no clinical or statistical differ-
ence in the incidence of HF between the imatinib and interferon
arms (O’Brien et al., 2003). Clinical data from 10 patients, who
developed left ventricular dysfunction after treatment with Ima-
tinib, was collected (Kerkela et al., 2006). LVEF had been nor-
mal prior to therapy but dropped to an average of 25% after a
mean of 7.2 months. However, it was concluded with later stud-
ies that this mainly affected elderly individuals with pre-existing
comorbidities.
Due to the concern of the potential cardiac damage induced by
this medication, the European Organization for Research on Treat-
ment Cancer-Italian Sarcoma Group-Australian Gastrointestinal
Trials Group (EORTC-ISG-AGITG) database was explored and
946 GIST patients were studied for cardiac damage secondary to
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Imatinib therapy (Verweij et al., 2007). Cardiac assessment was
based on the patient’s history and physical exam. Overall, 10
patients were reported to have had a cardiac event or reported
HF. However, when analyzed in more detail, two patients had pre-
vious HF due to previous AC exposure and two other patients
had known LV dysfunction, and most patients continued imatinib
without any further cardiac complications, concluding that HF
directly secondary to Imatinib was less likely.
Upon further investigation, 1,276 patients with CML who had
been enrolled in clinical trials of imatinib from 1998 to 2006 were
investigated for cardiac events secondary to Imatinib (Atallah et al.,
2007). Among these patients, 22 (1.8%) were reported as having
symptoms that could be attributed to HF, with 18 of these patients
having previous medical conditions predisposing them to cardiac
disease and 13 patients having previously known cytotoxic drugs.
The authors concluded that HF caused directly by imatinib is rare
and it was not possible at the time to establish a direct link between
the two due to the multiple cofounders.
Sunitinib (sutent)
Sunitinib is a multi-targeted TKI that prolongs survival in patients
with GIST and RCC. It targets vascular endothelial cell growth fac-
tor receptors (VEGFR)1–3, platelet derived growth factor recep-
tors (PDGRF) alpha and beta, FMS-like tyrosine kinase-3 (Flt-3),
c-kit (stem cell factor receptor), colony stimulating factor 1 recep-
tor (CSF1R), and the ret oncogene product (Chu et al., 2007).
The CV risk associated with sunitinib in patients with metastatic
GIST was evaluated in a retrospective study (Chu et al., 2007). All
CV events in 75 patients with imatinib-resistant, metastatic, GIST
had been enrolled in a phase I/II trial investigating the efficacy of
sunitinib. After the fourth cycle, more than 50% of patients were
started on beta blockers or ACEI for hypertension control. All had
a baseline LVEF of >50% and none had a history of HF. Of the
75 patients, 36 went off secondary to disease progression. Three
of 36 (8%) patients treated with sunitinib developed NYHA class
3–4 HF.
Motzer et al. (2006) reported that 10% of subjects in their
clinical trial experienced a drop in LVEF. However, this drop in
LVEF was not associated with clinical symptoms and was reversible
after modification of the dose or discontinuation of treatment.
Due to conflicting data and the lack of knowledge of the true
risk of HF with sunitinib, a meta-analysis was carried out in
order to determine the incidence and risk of developing HF in
patients receiving sunitinib therapy (Richards et al., 2011). Only
phase II and III studies were included and patients with signifi-
cant CV disease, dysrhythmias, prolongation of the QT interval,
or uncontrolled hypertension were excluded. Sixteen total stud-
ies with 6,935 patients were included as well as both randomized
and non-randomized studies. HF regardless of grade represented
a total incidence of 4.1% whereas high-grade HF represented an
incidence of 1.5%. An overall RR of developing all-grade HF was
1.81 and 3.3 for high-grade HF events.
Bevacizumab (avastin)
Vascular endothelial growth factor (VEGF) plays a role in tumor
growth, invasion, and metastasis by promoting tumor angiogene-
sis (Ranpura et al., 2010) and in knock-out mice, lacking the VEGF
gene, the myocardial walls were thinned and contractile function
was decreased (Giordano et al., 2001). Bevacizumab is a human-
ized monoclonal antibody that inhibits the activity of VEGF and
has been shown to be beneficial in the treatment of metastatic
colorectal cancer, non-small cell lung cancer, and breast cancer
(Izzedine et al., 2009). A meta-analysis was conducted studying
the risk of HF in breast cancer patients receiving bevacizumab
in randomized trials (Choueiri et al., 2011). This is of impor-
tance since many breast cancer patients have had prior exposure
to cardiotoxic agents such as AC and/or trastuzumab. The overall
incidence of high-grade HF was 1.6%. For the control group or
placebo-treated group, there was an incidence of 0.4%. The over-
all RR of developing high-grade HF with bevacizumab was 4.74.
When directly comparing the incidence and RR of HF with high-
versus low-dose bevacizumab, no significant difference was found.
The concomitant CTs administered were taxanes, capecitabine, or
ACs and there were no significant difference between the different
CTs and the incidence of HF.
The use of TKIs has drastically improved the survival and prog-
nosis of various malignancies. However, these molecules also play a
role in the function of cardiac cells and may impede on their func-
tion. In addition to the potential for hypertension as a related CV
consequence of TKI use, patients with previous cardiac risk factors
are at increased risk for TKI induced cardiotoxicity, therefore these
must be assessed prior to the beginning of treatment.
CARDIOVASCULAR THERAPIES FOR CHEMOTHERAPY
RELATED CARDIOTOXICITY
Anthracycline-induced cardiotoxicity has been well established
for many years and only a handful of prospective studies have
been published, exploring therapeutic options to treat or prevent
CIC (Table 1). Most data are based on findings reported in older
studies (Cardinale et al., 2010). Trastuzumab associated toxicity
usually responds to standard HF treatment or the discontinuation
of trastuzumab, although recovery rates may be lower in those who
have received prior ACs. The majority of trastuzumab-related car-
diac events are asymptomatic declines in LVEF and early detection
and management is crucial to recovery. There is very limited data
on specific CV therapeutics in the management of TKI induced
cardiotoxicity.
In 2005, Nakame et al. (2005) aimed to characterize acute
CHOP (cyclophosphamide, doxorubicin, Vincristine, and pred-
nisolone) induced cardiotoxicity using echocardiography, ECG
as well as serum cardiac markers in order to evaluate whether
or not Angiotensin II type 1 receptor blockers (ARBs) can pre-
vent acute CHOP induced cardiotoxicity in patients with Non-
Hodgkins Lymphoma (NHL). None of the patients had received
prior CT or radiation therapy and all had an LVEF>50% at base-
line. Forty patients with untreated NHL who were scheduled to
undergo CHOP therapy were randomized to receive 80 mg daily of
Valsartan vs. placebo, from the first day of CHOP therapy. The dox-
orubicin dose in the CT regime was 50 mg/m2. An echocardiogram
was performed at baseline, 3, 5, and 7 days after initiation of CHOP.
It was demonstrated that patients not treated with Valsartan had
an increased LVDd (end-diastolic diameter), BNP,ANP, QTc inter-
val. There were no significant differences with LV end-systolic
diameter, LVEF, E/A, and DcT. There was some impact on some
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Nakame et al. (2005) 40 Valsartan 80 mg daily vs. control BNP (pg/ml) 7 days
LVDD (mm)
QTc (ms)
Ewer et al. (2005) 38 Removal of trastuzumab±ACEI and
beta blockers (tolerated dose)
LVEF (%) 4.5 months (median)
Cardinale et al. (2006) 114 Enalapril 2.5–20 mg daily vs. control LVEF (%) 12 months
EDV (ml)
ESV (ml)
Kalay et al. (2006) 50 Carvedilol 12.5 mg daily vs. control LVEF (%) E/A ratio 6 months
Cardinale et al. (2010) 201 Enalapril± carvedilol (tolerated dose) LVEF (%) time to HF treatment
(months) NYHA functional class
36±27 months
Acar et al. (2011) 40 Atorvastatin 40 mg daily vs. control LVEF (%) 6 months
LVEDD (mm)
LVESD (mm)
LVEF, left ventricular ejection fraction.
BNP, brain natriuretic peptide.
ESV, end-systolic volume.
LVESD, left ventricular end-systolic diameter.
LVDD, left ventricular end-diastolic diameter.
EDV, end-diastolic volume.
LVEDD, left ventricular end-diastolic diameter.
specific CV parameters; Valsartan however, significantly inhibited
the dilatation of LVDd, elevation of BNP, and prolongation of the
QTc interval and QTc dispersion.
In 2005, Ewer et al. (2005) studied trastuzumab-related car-
diotoxicity. Of the 37 patients affected, 15 of these patients
experienced symptomatic HF. They were all treated with stan-
dard HF medications, including ACEI and beta-blockers. All of
the 20 patients with HF had some improvement in their LVEF
and significant symptomatic improvement when trastuzumab was
discontinued; however, two of the five patients who were not
treated with HF medications had persistent LV dysfunction when
reassessed approximately 6 months later. Once the LVEF stabi-
lized and HF symptoms improved, 25 of the 38 patients were
reintroduced to trastuzumab because they had a positive initial
response. Among those who restarted treatment, 22 of the 25
patients had stable LVEF measurements once trastuzumab was
reinitiated, without recurrences of HF during follow-up. LV dys-
function and/or HF reoccurred in the remaining three patients
and trastuzumab therapy was permanently discontinued. There-
fore, patients who experienced any form of cardiotoxicity while
receiving trastuzumab therapy generally recovered when it was
discontinued and this improvement occurred over a period of
months (mean time, 1.5 months).
A prospective, randomized clinical study evaluated the effect
of enalapril treatment on the prevention of cardiotoxicity in can-
cer patients undergoing high dose chemotherapy (HDC) that is
followed by an increase in TnI (Cardinale et al., 2006). Among
473 patients undergoing HDC, 114 showed increased TnI values
soon after HDC and participated in the study. All patients with
an early TnI value >0.07 ng/ml received enalapril vs. placebo. In
the ACEI group, enalapril was started 1 month after the end of
the last cycle of HDC and was continued for 1 year. Enalapril
was started at a dose of 2.5 mg daily and gradually increased to
20 mg once daily. Throughout the study, a progressive decline
in LVEF and an increase in end-diastolic and end-systolic vol-
umes were found only in the control subjects. Thirty one cardiac
events occurred during follow-up with the incidence highest in
the control subjects. Specifically, 14 events of “HF” occurred in
the control group and none in the ACEI group. Early treat-
ment with an ACEI, once myocardial damage becomes appar-
ent (rise in TnI), was postulated to prevent the development of
cardiotoxicity.
The use of carvedilol in preventing AC-induced cardiomyopa-
thy was evaluated in a single blind, placebo controlled study (Kalay
et al., 2006). The carvedilol group received 12.5 mg daily and
started prior to CT and maintained treatment for 6 months dur-
ing CT. None of the subjects received any prior CT or radiation
therapy. There was a greater drop in LVEF in patients who did
not receive beta blockers. In addition, E/A ratios were significantly
reduced on doppler studies in the control group, however, the
mortality difference between the two groups was not significant.
Of note is that carvedilol was the chosen agent since it has been
demonstrated to possess superior antioxidant and anti-apoptotic
properties in previous studies.
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In 2010, Cardinale et al. (2010) evaluated a large population
of symptomatic and asymptomatic patients with AC-induced car-
diomyopathy and examined their response to current HF medical
therapy. This prospective study included patients with evidence of
left ventricular systolic dysfunction (LVEF< 45%) secondary to
AC use. The primary end point was LVEF response to HF therapy.
Therapy with enalapril and subsequently carvedilol was initiated
after detection of LVEF impairment. In 201 patients, 72 received
only enalapril and 129 received both enalapril and carvedilol. Time
to HF treatment and NYHA functional class were selected as the
only independent predictors of lack of complete LVEF recovery.
When patients with both a time to HF treatment <6 months and
an NYHA class 1 or 2 were considered, positive predictive value for
complete LVEF recovery was 84% and negative predictive value
was 87%. If a time to HF treatment was greater than 6 months
duration or NYHA 3/4, no patient experienced LVEF recovery. As
observed in this study, baseline NYHA functional class 3 or 4 is a
strong predictor of lack of response to HF therapy.
The use of statins has been accepted as common practice to
prevent and treat atherosclerotic disease due to their lipid lower-
ing and anti-inflammatory effect. However, they also possess an
anti-oxidative effect which may be beneficial in preventing CIC. A
prospective study of 40 patients was performed in order to deter-
mine if the use of atorvastatin would prevent a decrease in LVEF
post AC CT (Acar et al., 2011). Patients were randomized into
a statin vs. control group. The statin group received 40 mg/day
of atorvastatin before CT and continued on this medication for
6 months afterward. On control echocardiography, 6 months post
CT, there was no significant difference in LVEF in the statin group
however there was a statistically significant drop in EF in the
control group. Additionally, in the control group, there was a
significant increase in LVEDD and LVESD.
A retrospective study evaluated the use of continuous statin
treatment on the development of HF in women with breast cancer,
who had undergone AC based CT (Seicean et al., 2012). The pri-
mary outcome was new onset HF causing hospitalization. Study
subjects were found on electronic medical records and women
with breast cancer on continuous statin treatment were matched
with controls. Based on observational data, patients who were
on continuous statin treatment were more likely to be older and
have hypertension and therefore be on concurrent ACEI and BB
therapy. The incidence of HF was found to be lower in the statin
group; specifically there were four cases of HF in the statin group
compared to 23 cases in the controls.
The lack of long-term studies has made it difficult to establish
a set of guidelines to assist us in the management of CIC. Further
prospective studies, investigating the ideal timing of introduction
of medical therapy and the choice of therapies are warranted in
order to preserve cardiac function.
EARLY PREDICTORS OF CHEMOTHERAPY-INDUCED CARDIOTOXICITY
As potential CV and imaging screening tools in order to detect the
presence of subclinical CV disease, biomarkers may be useful in
identifying patients at an elevated risk of disease. In addition, they
may be helpful as prognostic indicators in those who have already
developed CV sequelae and would be useful in guiding us in con-
current management (Ky and Carver, 2011). Several biomarkers
and imaging parameters have been examined in the context of
CIC in order identify or stratify risk in those patients that would




Cardiac troponins I and T are cardiac regulatory proteins that
control the calcium-mediated interaction of actin and myosin.
Cardiac troponin I is a marker of minor myocardial damage and it
is released by cardiac cells in proportion to the degree of myocar-
dial damage (Cardinale et al., 2000). Cardiac troponin I has not
been found outside the cardiac muscle, as opposed to cardiac tro-
ponin T where it is mildly expressed in skeletal muscle. However,
with the second generation assays, cardiac troponin T should only
be detected if it is arising rise cardiac tissue (Ricchiuti et al., 1998).
Two large studies were carried out in order to investigate the
value of Troponin I as an indicator of early myocardial damage
and as a predictor of future CV events in CIC. Following high
dose CT, troponin I measurements were used as a predictor of
the resulting CV damage (Cardinale et al., 2000). Two hundred
and four patients, previously treated with ACs or radiotherapy
were assigned to two groups. The cTnI+ group was defined by
a value ≥0.5 ng/ml, while the cTnI-group was defined by a value
<0.5 ng/ml. Patients in whom TnI were negative, on follow-up
echocardiography, tended to have a transient decrease in LVEF
after 3 months but recovered to an LVEF greater than 50% by 4–
7 months. Among patients in whom TnI were positive, the drop in
LVEF was more substantial from 3 months onward, continued to
drop and maintained at a decreased level until the end of follow-
up. The percentage of cTnI positivity increased in parallel with the
increasing number of the cycles performed.
The same authors set out to examine the potential impact of
the rise in TnI beyond the early rise in troponins (Cardinale et al.,
2004). A total of 703 patients were enrolled. Early troponins (E-
TnI) consisted of samples taken within 3 days after CT infusion
whereas late troponins (L-TnI) were drawn 1 month post CT.
Patients without TnI elevation after HDC had a good progno-
sis; no significant reduction in LVEF was observed in this group,
and a very low incidence of cardiac events (1%) occurred during
the follow-up. The PPV was 84% and NPV 99%. The high NPV
allows the identification of low-risk patients who may not require
very close cardiac surveillance following HDC.
Recently new generation highly sensitive Troponin T (hsTnT)
assay demonstrated prognostic value in a stable HF population
(Dodos et al., 2008). Forty three women were studied prior to,
in addition to 3 and 6 months post CT in order to assess whether
early biomarkers could predict the development of CIC in patients
treated with ACs and trastuzumab (Sawaya et al., 2011). Elevation
of high sensitivity troponin I cardiac markers at 3 months post
CT was able to detect a decrease in LVEF in six of nine patients,
therefore the authors concluded that this was an independent risk
factor for the development of cardiotoxicity at 6 months post CT.
Natriuretic peptides
Natriuretic peptides (ANP, BNP, and NT-proBNP) are produced
by the myocardium in response to wall strain and pressure
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overload. They have been recognized and incorporated in guide-
lines for diagnosis and management of HF (Horacek et al., 2007).
Plasma levels of natriuretic peptides have been shown to be
increased in patients with severe HF but also in those patients
with asymptomatic left ventricular dysfunction (Nousiainen et al.,
1999). Serum concentrations of natriuretic peptides have also been
measured in patients undergoing CT in order to try and predict
the risk of CV damage, but results have been less consistent than
the research with troponins. The few studies evaluating their use
will be presented.
Thirty adult patients with previously untreated non-Hodgkin’s
lymphoma, who were scheduled to receive CHOP, were prospec-
tively studied in order to determine whether these natriuretic
peptides could be used to predict impairment of left ventricu-
lar function (Nousiainen et al., 1999). LVEF was measured with
radionuclide ventriculography (RVG) and it was performed at
baseline and after the cumulative doxorubicin doses of 200, 400,
and 500 mg/m2. Natriuretic peptide measurements were taken
at baseline, before every treatment course and 4 weeks after the
last CHOP. ANP levels increased steadily after the doxorubicin
cumulative dose of 200 mg/m2 and reached significant levels at
the cumulative dose of 500 mg/m2. A trend was detected between
an increase in plasma NT-proANP and decrease in LVEF after the
cumulative doxorubicin dose of 500 mg/m2. Finally, there was a
trend between the increase in plasma BNP and the decrease in
LVEF after the cumulative doxorubicin dose of 400 mg/m2. This
study focused on systolic cardiac function and did not correlate
the natriuretic factors with any diastolic parameters.
The possible predictive role of NT-proBNP was evaluated in
a retrospective study of 52 patients treated with HDC, in whom
echo was performed regularly during a 1-year follow-up (Sandri
et al., 2005). NT-proBNP was measured in 52 patients in order to
evaluate a possible association with cardiac monitoring findings.
Cardiac function was assessed by echo at baseline and at 4 and
12 months after the end of treatment. NT-proBNP samples were
measured at baseline, at the end of the infusion, and 12, 24, 36,
and 72 h after the end of each CT cycle.
Patients were divided into three groups. Group A, plasma NT-
proBNP increased significantly immediately after the end of the
infusion, with high concentrations still present after 72 h. Group
B, NT-proBNP increased after 12–36 h from the end of treatment
but decreased toward baseline after 72 h and group C, NT-proBNP
decreased from baseline to 72 h. The mean ratio of peak early
to peak late flow velocities (E:A ratio) decreased significantly
over time in group A, whereas it remained unchanged in the
other two groups. LVEF was significantly decreased only in the
A group patients, with the mean value decreased below 50% after
12 months.
Twenty six patients with new acute leukemia, without any pre-
vious CT or radiation therapy, were studied in order to compare
the changes in biochemical markers with findings on echocardio-
gram (Horacek et al., 2007). Six months after CT, NT-proBNP
concentrations were correlated with systolic and diastolic LV dys-
function on echocardiogram. NT-proBNP’s were elevated in 23/26
patients after the first and last CT with ACs. Six months post com-
pletion of CT, 16 patients had persistent high levels and 4 patients
had levels above 500 ng/L. Only two patients with NT-proBNP
above 500 ng/L, 6 months after treatment, had echo signs of LV
dysfunction and clinical symptoms of HF. They were treated with
ACEI and diuretics. These two patients had NT-proBNP values
markedly elevated already after first and last CT with ANT.
Serum cTNT, BNP levels, and doppler echocardiographic index
for the detection and monitoring of AC-induced cardiotoxicity
over a period of 1 year in 100 adults undergoing CT were prospec-
tively assessed and compared (Dodos et al., 2008). Patients with no
prior use of AC therapy or mediastinal radiotherapy were included.
Of note, 18 patients had a history of systemic hypertension which
was well controlled under medication. These anti-hypertensive
medications may have masked a potential diastolic or systolic car-
diac decompensation. Overall, 15 patients developed a cardiac
event, defined as a reduction in absolute value >20% in LVEF
from baseline or a decline in absolute value >10% in LVEF from
baseline and below 55%. Among these patients, seven presented
with an additional reduction of the E/A ratio, three with an eleva-
tion of cTnT, while none exhibited an alteration of NT-proBNP.
No individual with early NT-proBNP increase developed systolic
dysfunction, and only four patients presented with a reduction of
the E/A ratio during follow-up. All of these patients had normal
NT-proBNP levels during further follow-up.
Even though cardiac biomarkers demonstrate some conflict-
ing results in the minimal research we have, they do show some
potential promise in their predictive ability of CIC. Their negative
predictive value may guide us in risk stratifying our patients and
determining which patients need a closer follow-up in the imme-
diate years following CT. Further studies are warranted in order
to follow these patients for an extended amount of time post CT
and to confirm whether these biomarkers are accurate enough to
be able to stratify our patients based on the early results.
Echocardiography
As mentioned, patients with cancer are living longer and the acute
and late-onset CIC is an ever growing concern. The early detection
of systolic or diastolic dysfunction secondary to these agents is an
integral part of our management strategies for these patients.
Left ventricular ejection fraction
The parameter for monitoring cardiotoxicity has traditionally
been the measurement of left ventricular ejection fraction (LVEF).
This parameter is most commonly assessed by either echocardio-
graphy or multigated acquisition scans (MUGA). Of note, there
are no clearly defined guidelines on the monitoring for left ven-
tricular systolic dysfunction for adults undergoing CT, namely
with regard to the preferred imaging modality, the frequency of
monitoring or what thresholds should be used. The advantages
and drawbacks of each of these imaging modalities are stated
in Table 2. To further improve the reproducibility and accuracy
of LVEF measurement, novel technological advances have been
applied in clinical practice. Intravenous administration of contrast
agents further enhances endocardial border delineation – through
opacification of the left ventricular chamber – and has resulted
in improving the intraobserver and inter-observer variability of
LVEF measurement (Hoffman et al., 2005). In addition, matrix-
array imaging for three-dimensional echocardiography overcomes
certain limitations by traditional 2-D echocardiography, such as
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Table 2 | Imaging modalities in the detection of HF.
Echocardiography MUGA
Advantages Non-invasive Lower inter- and observer
variability (<5%)
No radiation
Information on valvular function
and diastolic dysfunction
Lack of the need for
geometric remodeling
Drawbacks Inter and intra observer variability
are 8.8 and 6.8%, respectively
(in comparison to MRI)
Exposure to radioactivity
geometric assumptions, and has shown improved reproducibility
and accuracy when compared to 2-D echo using cardiac magnetic
resonance imaging as the gold standard (Qi et al., 2007).
Diastolic dysfunction parameters
Relying solely on the measurement of LVEF to detect CT-induced
myocardial damage leads us to overlook the subtle alterations of
the contractile properties of the myocardium since it is known
that LVEF is a late marker of cardiotoxicity. It remains uncer-
tain however whether cardiotoxicity, as defined by the Cardiac
Review Committee, can be predicted by any non-invasive index
of ventricular function (Stoddard et al., 1992). As in other disease
states, alterations in diastole may occur before systolic dysfunc-
tion. In fact, several studies have demonstrated that the use of
AC alter traditional diastolic parameters measured in echocar-
diography such as early peak flow velocity to atrial peak flow
velocity (E/A), deceleration time (DT), and isovolumetric relax-
ation time (IVRT; Marchandise et al., 1989; Dorup et al., 2004;
Ganame et al., 2007b; Pudil et al., 2008). Other investigators have
demonstrated reductions of the tissue-Doppler-derived peak early
diastolic velocity of the mitral annulus (E’), a surrogate marker of
diastolic dysfunction, in patients receiving AC (Nagy et al., 2006,
2008; Tassan-Mangina et al., 2006; Ho et al., 2010; Sawaya et al.,
2011).
Importantly, these decreases in tissue diastolic velocities have
not shown any relationship or predictive value for the later devel-
opment of cardiotoxicity, as defined by the Cardiac Review Com-
mittee. In Sawaya et al.’s (2011), the 6-month follow-up failed to
demonstrate any predictive value. Whether these global alterations
in diastolic function may relate to later onset of cardiotoxicity
remains to be studied.
Strain and strain rate
As previously stated, because LVEF is a late marker of CIC, novel
methods of detecting cardiac damage have been explored and
studied. Among those,myocardial strain and strain rate by speckle-
tracking imaging have emerged as useful tools in the arsenal of
clinical echocardiography.
Strain is defined as a change in length or percent change from
the original or unstressed dimension. It reflects the deformation
of a myocardial segment and describes the contraction/relaxation
pattern of the myocardium. Strain rate is the rate of this defor-
mation and is an index of left ventricular contractility. Three
main deformation components can be interrogated: the longi-
tudinal, radial, and circumferential components (5 – Figure 2b of
the Mor-Avi et al. guideline document).
Parameters used in 2-D clinical echocardiography, which
include fractional shortening (FS) and ejection fraction, evaluate
global LV function, and thus, regional myocardial function may be
overlooked. This could be important as regional dysfunction may
precede global LV dysfunction. Additionally, LVEF and FS values
depend largely on preload and afterload. Deformation parame-
ters, such as strain and strain rate, have been demonstrated to be
less load dependent and have potential value for the quantification
of global and regional systolic and diastolic myocardial function
(Ganame et al., 2007b).
One of the first human studies to show decreases in strain from
CT was performed on 13 children scheduled to receive AC for
various malignancies (Ganame et al., 2007a). Echocardiographic
studies were performed before the first dose and<2 h after each of
the first three doses of AC to assess its acute cardiac effects. Com-
pared with baseline, a significant decrease in the LV, SF, and LVEF
was only evident after the second dose of AC, whereas decreased
strain and strain rate decreased significantly after the first dose and
remained so after subsequent doses (Ganame et al., 2007a).
In another study by Ganame et al. (2007b), 56 patients with
various malignancies (ALL, lymphoma, solid tumors, AML) were
studied approximately 5 years after receiving anthracycline therapy
to investigate whether changes in strain and strain rate would be
detected after CT. Whereas FS and ejection fraction were not dif-
ferent between subjects and controls, peak systolic strain rate and
strain values were significantly lower in the anthracycline group.
Potential explanations include the fact that cardiac changes may
be so localized to only certain myocardial segments, they did not
result in changes in global ejection parameters. Moreover, diastolic
parameters such as IVRT were altered indicating that small subtle
changes may have occurred (Ganame et al., 2007b).
Sawaya et al. (2011) demonstrated that longitudinal strain, in
conjunction with cardiac troponin, predicted the development of
cardiotoxicity in patients treated with AC and trastuzumab. In this
prospective study of 43 women studied prior to, 3 and 6 months
after CT, investigators studied whether early echocardiographic
measurements of myocardial deformation and biomarkers could
predict the development of CIC in patients treated with AC and
trastuzumab. Peak systolic radial, longitudinal, and circumferen-
tial strain decreased before any decrease in LVEF. Nine patients
met the criteria for cardiotoxicity. Decreases in longitudinal strain
and radial strain and elevated hsTnI at 3 months were predictive of
patients who developed cardiotoxicity at 6 months. The change of
LVEF at 3 months was not predictive of later cardiotoxicity. More-
over, patients with both findings had a ninefold increase in the risk
of CIC, whereas the absence of either conferred significant protec-
tion where only 3% develop CIC. Explanations for these findings
have included the fact that CIC may have a regional pattern – the
function of some myocardial segments may compensate for other
dysfunctional segments leading to a preserved LVEF in the early
stages of the cardiotoxicity. Another possible contributing factor
explaining for the higher sensitivity of strain compared to the LVEF
may be the difference in inter-observer variability. Strain mea-
surement involves the averaging of the automated measurement
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of multiple segments, whereas LVEF assessment involves a tracing
leading to a single measurement.
The same group studied 81 patients over a 1-year follow-up and
confirmed that systolic longitudinal myocardial strain and ultra-
sensitive troponin I measured at the completion of AC therapy
were predictive of subsequent cardiotoxicity (Sawaya et al., 2012).
These multiple studies have demonstrated that parameters such
as diastolic dysfunction and abnormalities of deformation para-
meters (strain) precede changes in LVEF and symptomatic HF. It
is difficult to state a definite conclusion that alterations to these
parameters lead to chronic cardiotoxicity since follow-up times
throughout these studies have been relatively short – studies with
longer follow-up periods are much needed. However, what we can
derive from these studies is that there is a potential opportunity
window to introduce cardioprotective medications in order to pre-
vent any long-term sequelae. Joint efforts to further study whether
early initiation of cardioprotective medication changes outcome
are currently underway.
Clinical predictors
Cardiovascular disease had become a significant issue in can-
cer survivors who have received previous CT, especially ACs.
Established modifiable and non-modifiable risk factors such as
hypertension, diabetes, and obesity, may predispose individuals to
develop CV disease in the context of receiving CT.
In order to investigate the risk factors for the development of
late cardiotoxicity following treatment with ACs, a retrospective
study analyzed the onset of late cardiac damage by measuring
LVEF, and FS in patients treated with doxorubicin for lymphoma
(Hequet et al., 2004). Prior to CT, 18% of patients had a diagnosis
of hypertension. CV risk factors, such as hypertension, diabetes,
hypercholesterolemia, obesity, familial history of cardiac disease,
and smoking were analyzed, and only obesity was significantly
associated with decreased FS.
Another retrospective cohort study in patients with advanced
NHL, who had received at least six cycles of doxorubicin, compared
the incidence of CV disease in the EORTC cohort compared with
the general population (Moser et al., 2006). The risk of chronic HF
was significantly increased in patients treated for aggressive NHL
compared to the general population as opposed to a matched risk
of coronary artery disease. Age at the start of NHL treatment, pre-
existing hypertension, and salvage treatments of any type were risk
factors for developing a CV event.
In a large registry, over 40,000 women with breast cancer were
analyzed through the Surveillance, Epidemiology, and End Results
(SEER) database (Pinder et al., 2007). Coronary artery disease,
emphysema, diabetes, hypertension, and peripheral vascular dis-
ease were significant predictors of a diagnosis of HF post AC CT.
Data from the SEER database were analyzed in order to investigate
risk factors of future CV disease in patients with a diagnosis of
diffuse large B-cell lymphoma (DLBCL; Hershman et al., 2008).
The risk of HF increased in patients with NHL, with the patient’s
age and history of coronary heart disease, valvular heart disease,
hypertension, diabetes, cigarette smoking, or obesity. Both hyper-
tension and diabetes were associated with an increased prevalence
of HF; however in a separate model in this same study, only
hypertension was associated with doxorubicin cardiotoxicity.
A retrospective, case-control study, of 63 patients who had
undergone hematopoietic stem cell transplant (HCT), evaluated
the role of comorbidities in the development of late CV disease
(Armenian et al., 2010). Cases were significantly more likely than
controls to have been diagnosed with hypertension before HCT
and to have a higher BMI at the time of HCT.
There are limited studies investigating the association or the
influence of pre-existing CV risk factors on the development of
HF post CT. The studies that have been published are mostly in
association with ACs and it would be of interest to explore associ-
ations with other CT such as TKI’s, which are being administered
with increasing frequency. By understanding the impact of CV
risk factors on the potential development of CIC, we can further
study the impact on prophylactically treating these patients with
cardioprotective strategies prior to, throughout, and post CT.
CONCLUSION
There are several established pre-existing modifiable and non-
modifiable risk factors that predispose individuals to CV disease,
some of which include hypertension, diabetes, and obesity. CT
agents used in cancer therapy, however, should also be considered
themselves as CV “risk factors” when evaluating cancer patients
with CV symptoms. Treatment of such patients with established
toxicity related to CT remains a challenge for oncologists and
cardiologists alike.
In addition, some cancer patients may have no CV symptoms
and have pre-clinical findings that may predict the development
of symptoms such as HF. Proper screening using novel imaging
techniques and serological testing, along with strategies aimed at
close clinical monitoring of these patients remains another sig-
nificant challenge for all specialists involved in the care of cancer
patients. Additionally, in the context of multi-modality therapy
with chemotherapeutic agents and radiotherapy, clinicians must
consider the potential interactions of these treatments. Patients
with a history of radiation therapy for malignancies are poten-
tially more susceptible to cardiotoxic effects of standard and novel
chemotherapies.
Currently, there are a growing number of centers in North
America that are establishing “cardiology-oncology clinics.”
Improving communication between specialists in both oncology
and CV medicine specialties will not only help advance clinical
care, but will also promote clinical research in this rapidly growing
field in medicine.
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